Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
idiotype mRNA vaccine
- Development stage
- Preclinical
- Lead developer
- Stanford University
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intramuscular
01
Overview
The idiotype mRNA vaccine is a personalized therapeutic cancer vaccine designed to treat B-cell lymphoma by targeting the unique idiotype of the B-cell receptor (BCR) expressed on clonal tumor cells. Developed by researchers at Stanford University, the vaccine utilizes mRNA encoding the heavy and light chain variable regions of the patient-specific BCR. To enhance antigen presentation, the construct includes an MHC class I trafficking domain (MITD). The mRNA is formulated with charge-altering releasable transporters (CARTs), a polymeric delivery system that releases the mRNA within antigen-presenting cells. When co-administered with a TLR9 ligand adjuvant (such as CpG), the vaccine induces a robust polyclonal T-cell response, including cytolytic CD8+ T cells, leading to significant tumor growth reduction in preclinical models.
- Other names
- A20 idiotype mRNA vaccineA-20 idiotype mRNA vaccineA 20 idiotype mRNA vaccineidiotype mRNA therapeutic vaccine
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)TLR9 (Toll-like receptor 9)Id (Tumor-specific idiotype immunoglobulin)
Beyond the preview
Go deeper on idiotype mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on idiotype mRNA vaccine.